Rating neurologic impairment in multiple sclerosis
An expanded disability status scale (EDSS)
Abstract
One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Copyright
© 1983 by the American Academy of Neurology.
Publication History
Published online: November 1, 1983
Published in issue: November 1983
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Associations between serum levels of alpha-calcitonin gene-related peptide and clinical features of neuromyelitis optica spectrum disorders, Journal of Neuroimmunology, 404, (578615), (2025).https://doi.org/10.1016/j.jneuroim.2025.578615
- Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis, Multiple Sclerosis and Related Disorders, 98, (106423), (2025).https://doi.org/10.1016/j.msard.2025.106423
- Epidemiology of aquaporin-4 seropositive neuromyelitis optica spectrum disorder in the Alicante health area, Spain: A population-based study, Multiple Sclerosis and Related Disorders, 98, (106422), (2025).https://doi.org/10.1016/j.msard.2025.106422
- Effects of 16-week progressive resistance training on neurodegeneration in people with progressive multiple sclerosis: An extended baseline within-person trial, Multiple Sclerosis and Related Disorders, 98, (106411), (2025).https://doi.org/10.1016/j.msard.2025.106411
- The utility of serum neurofilament light chain in MOGAD: Current insights and future directions, Multiple Sclerosis and Related Disorders, 98, (106410), (2025).https://doi.org/10.1016/j.msard.2025.106410
- The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study, The Lancet Regional Health - Europe, 53, (101302), (2025).https://doi.org/10.1016/j.lanepe.2025.101302
- Study of sleep abnormalities in patients with NMOSD-MOG related disorders, Multiple Sclerosis and Related Disorders, 97, (106405), (2025).https://doi.org/10.1016/j.msard.2025.106405
- Comparison of vision-related quality of life in NMOSD and MOGAD, Multiple Sclerosis and Related Disorders, 97, (106392), (2025).https://doi.org/10.1016/j.msard.2025.106392
- Validation of the Patient-Determined Disease Steps in ambulatory older adults with multiple sclerosis, Multiple Sclerosis and Related Disorders, 97, (106391), (2025).https://doi.org/10.1016/j.msard.2025.106391
- Clinical and psychological factors associated with fear of relapse in people with multiple sclerosis: A cross-sectional study, Journal of Clinical Neuroscience, 135, (111210), (2025).https://doi.org/10.1016/j.jocn.2025.111210
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.